CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 164 enrolled
Drug / intervention
Bleomycin Sulfate +11 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01132807
NCT01132807Phase 2Completed
CompareCT.gov

Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

Alliance for Clinical Trials in Oncology·interventional·Posted May 28, 2010·Updated Jun 14, 2021

In Brief

A Phase 2 clinical trial evaluating Bleomycin Sulfate, Doxorubicin Hydrochloride, and 10 other interventions for Lymphoma. Completed, enrolled 164 participants across 95 sites.

Detailed Summary

This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started. Comparing results of diagnostic procedures, such as PET scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 28, 2010
Enrollment StartMay 1, 2010
Primary CompletionFeb 1, 2016
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 16.1 years ago

Interventions

Bleomycin Sulfatebiological

Given IV

Doxorubicin Hydrochloridedrug

Given IV

Procarbazine Hydrochloridedrug

Given PO

Vinblastine Sulfatedrug

Given IV

Dacarbazinedrug

Given IV

Cyclophosphamidedrug

Given IV

Etoposide phosphatedrug

Given IV

prednisonedrug

Given PO

Radiation Therapydrug

Undergo radiation therapy

Fludeoxyglucose F-18radiation

Undergo FDG PET/CT

computed tomographyprocedure

Undergo FDG PET/CT

Positron Emission Tomographyprocedure

Undergo FDG PET/CT